Tuberculosis risk and prevention in travelers - What about BCG?

Journal of Travel Medicine

Volumn 4, Issue 2, 1997, Pages 76-82

  Houston, Stan ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; TUBERCULIN;

ABSCESS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INFECTION RISK; LYMPHADENITIS; REVIEW; TRAVEL; TUBERCULIN TEST; TUBERCULOSIS; ULCER;

EID: 0030852735     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1997.tb00784.x     Document Type: Review

References (96)

1. Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990;65:6-24.
2. Styblo K. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis 1989;11(Suppl 2):S339-S346.
3. Hill DR. Immunizations for foreign travel. Yale J Biol Med 1992;65:293-315.
4. Veen J. BCG-vaccinate voor reizigers naar de tropen. Ned Tijdschr Geneeskd 1987;131:811-812.
5. Walker E, Williams G. ABC of healthy travel. 3rd Ed. British Medical Journal, 1989.
6. Mitchison D. Tuberculosis in travelers. In: Dawood R, ed. Travellers' health. Oxford: Oxford University Press, 1986:67-70.
7. Gooskens VH, Klokke AH. Primary cutaneous tuberculosis complex as an imported disease. Ned Tijdschr Geneeskd 1977;121(19):785-786.
8. Aldea MJ, Lezcano MA, Esteban A, et al. Pleuropulmonary tuberculosis caused by Mycobacterium africanum in a white male (Letter). Enferm Infecc Microbiol Clin 1990;8:64-65.
9. Steffen R. Health risks for short-term travellers. In: Steffen R, Lobel HO, Haworth J, Bradley DJ, eds. Travel medicine. Berlin: Springer Verlag, 1989:27-36.
10. Frame JD, Lange WR, Frankenfield DL. Mortality trends of American missionaries in Africa, 1945-1985. Am J Trop Med Hyg 1992;46(6):686-690.
11. McCarthy OR. Asian immigrant tuberculosis - the effect of visiting Asia. Br J Dis Chest 1984;78:248-253.
12. Hynes N, ed. The health of the volunteer. The 1994 annual volunteer health status report. Peace Corps, 1995; Appendix B.
13. Centers for Disease Control. Global estimates of future, tuberculosis morbidity and mortality. MMWR 1993;42: 961-964.
14. Kenyon TA, Valway SE, Ihle WW, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996;334:933-938.
15. Ferguson RG. BCG vaccination in hospitals and sanatoria of Saskatchewan. A study carried out by the National Research Council of Canada. Am Rev Tuberc 1946;54:325-329.
16. Ferguson RG. BCG vaccination in hospitals and sanatoria of Saskatchewan. A study carried out by the National Research Council of Canada. Can J Public Health 1946;37:435-151.
17. Chan JC, Tabak JI. Risk of tuberculosis infection among house staff in an urban teaching hospital. South Med J 1985; 78:1061-1064.
18. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
19. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550.
20. Di Perri G, Danzi MC, De Checchi G, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;30:1502-1504.
21. IUATLD and WHO. Control of tuberculosis transmission in health care settings. Tuber Lung Dis 1994;75:94-95.
22. Centers for Disease Control. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43(RR-13):1-131.
23. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
24. IUAT Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull Int Union Tuberc Lung Dis 1982;60:555-564.
25. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978;117:991-1001.
26. Barrett-Connor E. The epidemiology of tuberculosis in physicians. JAMA 1979;241:33-38.
27. Geiseler PJ, Nelson KE, Crispin RG. Tuberculosis in physicians: compliance with preventive measures. Am Rev Respir Dis 1987;135:3-9.
28. Wobeser W, To T, Hoeppner VH. The outcome of chemoprophylaxis on tuberculosis prevention in the Canadian Plains Indian. Clin Invest Med 1989;12:149-153.
29. Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med 1995;122:906-912.
30. Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995;333:222-227.
31. Marfan A. Archives de Medicine General 1886;(i):423-434, 575-589.
32. Centers for Disease Control. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the Advisory Committee for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR 1996;45(RR-4):1-18.
33. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia. Public Health Rep 1976;91: 276-280.
34. Comstock GW, Livesay VT, Woolpert SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1974;64:283-291.
35. Comstock GW, Webster R.Tuberculosis studies in Muscogee County, Georgia.Am Rev Respir Dis 1969;100:839-845.
36. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1980;72(Suppl):1-74.
37. Aronson JD. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948; 58:255-281.
38. Coetzee AM, Berjak J. BCG in the prevention of tuberculosis in an adult population. Proc Mine Med Off Assoc 1986; 48:41-53.
39. Ferguson RG, Simes AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949;30:5-11.
40. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 1977;2:293-295.
41. Rosenthal SR, Loewinsohn E, Graham ML, et al. BCG vaccination in tuberculous households. Am Rev Respir Dis 1961;84:690-704.
42. Rosenthal SR, Loewinsohn E, Graham ML, et al. BCG vaccination against tuberculosis in Chicago; a twenty-year study statistically analyzed. Pediatrics 1961;28:622-641.
43. Vandiviere HM, Dworski M, Melvin IG, et al. Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. Am Rev Respir Dis 1973;108: 301-313.
44. Stein SC, Aronson JK. The occurrence of pulmonary lesions in BCG-vaccinated and unvaccinated persons. Am Rev Tuberc 1953;68:695-712.
45. Frimodt-Moller J, Acharyulu GS, Pillai KK. Observations on the protective effect of BCG vaccination in a south Indian rural population. Bull Int Union Tuberc 1973;48:40-52.
46. Levine MI, Sackett MF. Results of BCG immunization in New York City. Am Rev Tuberc 1946;53:517-532.
47. Aronson JD, Aronson CF, Taylor HC. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med 1958;101:881-893.
48. Houston S, Fanning A, Soskolne CL, Fraser N. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis. Am J Epidemiol 1990;131:340-349.
49. Miceli I, de Kantor I, Colaiacovo D, et al. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 1988; 17:629-634.
50. Myint TT, Win H, Aye HH, Kyaw-Myint TO. Case-control study on evaluation of BCG vaccination of newborns in Rangoon, Burma. Ann Trop Paediatr 1987;7:159-166.
51. Packe GE, Innes JA. Protective effect of BCG vaccination in infant Asians: a case-control study. Arch Dis Child 1988;63: 277-281.
52. Rodrigues LC, Noel Gill O, Smith PG. BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J Epidemiol Community Health 1991;45:78-80.
53. Sirinavin S, Chotpitayasunondh T, Suwanjutha S, et al. Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J 1991;10: 359-365.
54. Young TK, Hershfield ES. A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health 1986;76:783-786.
55. Patel A, Schofield F, Sisking V, et al. Case-control evaluation of a school-age BCG vaccination programme in subtropical Australia. Bull World Health Organ 1991;69:425-433.
56. Shapiro C, Cook N, Evans D, et al. A case-control study of BCG and childhood tuberculosis in Cali, Colombia. Int J Epidemiol 1985;14:441-446.
57. Clemens JD, Jackie JH, Chuong JH, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1982;249:2362-2369.
58. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702.
59. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis 1995;20:982-991.
60. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-1158.
61. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96:29-35.
62. Brewer TF, Colditz GA. Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995;20:136-142.
63. Ponnighaus JM, Fine PEM, Sterne JAC, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992;339:636-639.
64. Stanley SJ, Howland C, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda: final results. J Hyg(Camb) 1981;87:223-248.
65. Brewer TF, Colditz GA. Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995; 20:126-135.
66. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966;94:553-568.
67. Springett VH, Sutherland I. A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 1994;75:227-233.
68. Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969;99(4Pt2):1-132.
69. Wahdan MH, Serie C, Cerisier Y. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J Infect Dis 1982;145:292-295.
70. Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987(i):1049-1052.
71. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-348.
72. Ward J, Brenneman G, Letson GW, et al. Limited efficacy of a Haemophilia influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990;323:1393-1400.
73. Lotte A, ten Dam HG, Henderson R. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc 1988;63:47-83.
74. Tardieu M, Truffot-Pernot C, Carriere JP, et al. Tuberculosis meningitis due to BCG in two previously healthy children. Lancet 1988;(i):440-441.
75. Karup Pedersen F, Engbaek HC, Hertz H, Vergmann B. Fatal BCG infection in an immunocompetent girl. Acta Paediatr Scand 1978;67:519-523.
76. Casanova J-L, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. Lancet 1995;346:581.
77. Morrison WL, Webb WJ, Rubenstein AJ. Meningitis after BCG vaccination. Lancet 1988;(i):654-655.
78. Weltman AC, Rose DN. The safety of bacille Calmette-Guérin vaccination in HIV infection and AIDS. AIDS 1993;7:149-157.
79. Global Programme on AIDS and Expanded Programme on Immunization. Joint WHO/UNICEF statement on early immunization for HIV-infected children. Wkly Epidemiol Rec 1989;7:48-49.
80. Comstock GW, Edwards LB, Nabangxang H. Tuberculin skin sensitivity to fifteen years after BCG vaccination. Am Rev Respir Dis 1971;103:572-575.
81. Snider DE. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 1985;253:3438-3439.
82. Karalliedde S, Katugaha LP, Uragoda CG.Tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987;68:33-38.
83. Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics 1965;36:624-627.
84. Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. Bull World Health Organ 1972;47:49-58.
85. Ashley MJ, Siebenman CO. Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J 1967;97:1335-1339.
86. Joncas JH, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J 1975; 113:127-128.
87. Sinha DP, Bang FB. Protein and calorie malnutrition, cell-mediated immunity, and BCG vaccination in children from rural West Bengal. Lancet 1976;(ii):531-534.
88. Guld J, Waaler H, Sundaresan TK, et al. The duration of BCG induced tuberculin skin sensitivity in children, and its irrelevance for re vaccination. Bull World Health Organ 1968;39: 829-836.
89. Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992;145:621-625.
90. Johnson H, Lee B, Doherty E, et al. Tuberculin sensitivity and the BCG scar in tuberculosis contacts. Tuber Lung Dis 1995; 76:122-125.
91. Young TK, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuber Lung Dis 1992;73:94-100.
92. Tuberculosis Committee, Canadian Thoracic Society. Essentials of tuberculosis control for the practising physician. Can Med Assoc J 1994;150:1561-1571.
93. Hart PD, Sutherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in tuberculin sensitivity and to technical variations in the vaccines. Tubercle 1967;48:201-210.
94. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988;138:479-480.
95. Fine PEM, Sterne JAC, Ponnighaus JM, Rees RJW. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994;344:1245-1249.
96. Greenberg PD, Lax KG, Schlechter CB. Tuberculosis in house staff: a decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991;143:490-495.